Literature DB >> 29318576

Comparing transfusion reaction risks for various plasma products - an analysis of 7 years of ISTARE haemovigilance data.

Nicholas H Saadah1,2, Johanna G van der Bom1,2, Johanna C Wiersum-Osselton3,4,5, Clive Richardson5,6, Rutger A Middelburg1,2, Constantina Politis5,7, Philippe Renaudier5,8, Pierre Robillard5,9, Martin R Schipperus4,10.   

Abstract

Plasma transfusions may result in transfusion reactions. We used the International Surveillance of Transfusion-Associated Reactions and Events (ISTARE) database, containing yearly reported national annual aggregate data on transfusion reactions from participating countries, to investigate risks of plasma transfusion reactions and compare transfusion reaction risks for different plasma types. We calculated risks for plasma transfusion reactions and compared transfusion reaction risks between plasma types using random effects regression on repeated measures. The ISTARE database contains data from 23 countries, reporting units issued and/or transfused and transfusion reactions observed for some portion of 7 years (2006-2012). Interquartile ranges (IQRs) of plasma transfusion reaction risks were: allergic reactions (5·6-72·2 reactions/105 units transfused); febrile non-haemolytic transfusion reactions (0-9·1); transfusion-associated circulatory overload (0-1·9); transfusion related acute lung injury (TRALI) (0-1·2); and hypotensive reactions (0-0·6). Apheresis plasma was associated with more allergic reactions [odds ratio (OR) = 1·29 (95% confidence interval: 1·19-1·40)] and hypotensive reactions [OR = 2·17 (1·38-3·41)] than whole blood-derived plasma. Pathogen-inactivated plasma was associated with fewer transfusion reactions than untreated plasma.
© 2018 John Wiley & Sons Ltd.

Entities:  

Keywords:  haemovigilance; plasma transfusion; transfusion reactions

Mesh:

Year:  2018        PMID: 29318576     DOI: 10.1111/bjh.15082

Source DB:  PubMed          Journal:  Br J Haematol        ISSN: 0007-1048            Impact factor:   6.998


  4 in total

1.  Safety and tolerability of solvent/detergent-treated plasma for pediatric patients requiring therapeutic plasma exchange: An open-label, multicenter, postmarketing study.

Authors:  Cassandra D Josephson; Stuart Goldstein; David Askenazi; Claudia S Cohn; Philip C Spinella; Ara Metjian; Ross M Fasano; Lejla Music-Aplenc
Journal:  Transfusion       Date:  2021-12-20       Impact factor: 3.337

Review 2.  Methylene blue-treated plasma, versus quarantine fresh frozen plasma, for acute thrombotic thrombocytopenic purpura treatment: Comparison between centres and critical review on longitudinal data.

Authors:  José Luis Arroyo; Eva Martínez; Cristina Amunárriz; Carmen Muñoz; Iñigo Romón; Ignacio Álvarez; José María García
Journal:  Transfus Apher Sci       Date:  2020-04-12       Impact factor: 1.764

3.  Transition from fresh frozen plasma to solvent/detergent plasma in the Netherlands: comparing clinical use and transfusion reaction risks.

Authors:  Nicholas H Saadah; Martin R Schipperus; Johanna C Wiersum-Osselton; Marian G van Kraaij; Camila Caram-Deelder; Erik A M Beckers; Anja Leyte; Jan M M Rondeel; Karen M K de Vooght; Floor Weerkamp; Jaap Jan Zwaginga; Johanna G van der Bom
Journal:  Haematologica       Date:  2019-07-04       Impact factor: 9.941

4.  Why Does the Precautionary Principle Suffice for Blood Regulation?

Authors:  Alexandra Seifner; Anthony W Fox
Journal:  Pharmaceut Med       Date:  2021-09-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.